US 12,460,013 B2
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
Myron Arlen, Great Neck, NY (US); J. Andrew Bristol, Rockville, MD (US); Ariel Hollinshead, Bethesda, MD (US); and Kwong Tsang, Bethesda, MD (US)
Assigned to Precision Biologics, Inc., Bethesda, MD (US)
Filed by PRECISION BIOLOGICS, INC., Bethesda, MD (US)
Filed on Dec. 16, 2022, as Appl. No. 18/067,142.
Application 18/067,142 is a division of application No. 16/438,886, filed on Jun. 12, 2019, granted, now 11,572,413.
Application 16/438,886 is a division of application No. 15/429,276, filed on Feb. 10, 2017, granted, now 10,364,295, issued on Jul. 30, 2019.
Application 15/429,276 is a division of application No. 14/739,701, filed on Jun. 15, 2015, granted, now 9,605,077, issued on Mar. 28, 2017.
Application 14/739,701 is a division of application No. 13/012,679, filed on Jan. 24, 2011, granted, now 9,169,326, issued on Oct. 27, 2015.
Application 13/012,679 is a division of application No. 12/825,022, filed on Jun. 28, 2010, granted, now 8,535,667, issued on Sep. 17, 2013.
Application 12/000,701 is a division of application No. 11/404,566, filed on Apr. 14, 2006, granted, now 7,314,622, issued on Jan. 1, 2008.
Application 12/825,022 is a continuation of application No. 12/000,701, filed on Dec. 17, 2007, granted, now 7,763,720, issued on Jul. 27, 2010.
Claims priority of provisional application 60/671,481, filed on Apr. 15, 2005.
Prior Publication US 2023/0203190 A1, Jun. 29, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07H 21/04 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/3076 (2013.01) [A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07H 21/04 (2013.01); C07K 16/303 (2013.01); C07K 16/3046 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/32 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01)] 12 Claims
 
1. An isolated recombinant monoclonal antibody or an antigen-binding portion thereof selected from:
(i) one comprising a light chain component and a heavy chain component, wherein said light chain component contains a CDR1 having the amino acid sequence SASSSISYMY (SEQ ID NO: 7), a CDR2 having the amino acid sequence DTSKLAS (SEQ ID NO:8), and a CDR3 having the amino acid sequence HQRDSYPWT (SEQ ID NO:9); and wherein said heavy chain component contains a CDR1 having the amino acid sequence SKFGVN (SEQ ID NO:10), a CDR2 having the amino acid sequence VIWGDGSTSYNSGLIS (SEQ ID NO:11), and a CDR3 having the amino acid sequence CVKPGGDY (SEQ ID NO:12); which antibody, or antigen-binding portion thereof binds to the human colorectal and pancreatic carcinoma-associated antigen (CPAA); or
(ii) one consisting of an antibody variable region light chain comprising the peptides SASSSISYMY (SEQ ID NO:7), DTSKLAS (SEQ ID NO:8), and HQRDSYPWT (SEQ ID NO: 9); and an antibody variable region heavy chain comprising the peptides SKFGVN (SEQ ID NO:10), VTWGDGSTSYNSGLTS (SEQ ID NO: 11-), and CVKPGGDY (SEQ ID NO:12); which antibody variable region binds to human colorectal and pancreatic carcinoma-associated antigen (CPAA).